Page values for "Alendronate"

Nav

"Medicines" values

1 row is stored for this page

Field	Field type	Value
generic	`String`	Alendronate
brand	`String`	Fosamax, Binosto
structure	`File`
classes	List of `String`, delimiter: `,`	[[:Category:Bisphosphonates\|Bisphosphonate (nitrogen-containing)]] • [[:Category:Antiresorptives\|Antiresorptive]] • [[:Category:Osteoporosis_medications\|Osteoporosis medication]]
mechanism	`String`	'"`UNIQ--vote-000006BE-QINU`"' Drug-holiday concept (3-5 years on, 1-2 years off) emerged from FLEX and long-term safety data balancing fracture protection against atypical femoral fracture and osteonecrosis of the jaw signals'"`UNIQ--ref-000006BF-QINU`"'.
uses	`String`	'"`UNIQ--vote-000006C0-QINU`"', '"`UNIQ--vote-000006C1-QINU`"', '"`UNIQ--vote-000006C2-QINU`"'
starting_dose	`String`	Treatment 70 mg PO once weekly (or 10 mg daily); prevention 35 mg weekly (or 5 mg daily); always taken first thing in the morning with a full glass of water, remaining upright for 30 minutes
preparations	`String`	5, 10, 35, 40, 70 mg tablets; 70 mg/75 mL oral solution; 70 mg effervescent (Binosto)
fda_max	`String`	70 mg/week treatment; 40 mg/d for 6 months in Paget's
pill_id	`Text`
routes	List of `String`, delimiter: `,`	Oral
onset	`String`	Bone marker reduction within weeks; BMD improvement at 1-3 years; fracture-risk reduction documented at 3-5 years
duration	`String`	Weeks; bone retention years
halflife	`String`	Plasma ~3 hours; bone half-life ~10 years'"`UNIQ--ref-000006C3-QINU`"'
bioavailability	`String`	<1% (oral; further reduced by food, calcium, iron, antacids; hence the strict fasting/upright dosing rules)'"`UNIQ--ref-000006C4-QINU`"'
pregnancy	`String`	Long-term skeletal retention is a concern given the unknown effect on developing fetal bone; generally avoided.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed\|citation needed]]]</sup>
legal	`String`	[[USLegal:Prescription only\|Rx-only]] in US